Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
24.02
-1.76 (-6.83%)
Jan 30, 2026, 4:00 PM EST - Market closed
Pelthos Therapeutics Revenue
Pelthos Therapeutics had revenue of $7.41M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $7.41M.
Revenue (ttm)
$7.41M
Revenue Growth
n/a
P/S Ratio
4.01
Revenue / Employee
$673,273
Employees
11
Market Cap
74.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 199.93K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPTHS News
- 15 days ago - Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics - Business Wire
- 18 days ago - Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance - GlobeNewsWire
- 26 days ago - Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - GlobeNewsWire
- 2 months ago - Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely - Seeking Alpha
- 2 months ago - Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 3 months ago - Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - GlobeNewsWire
- 3 months ago - Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 - GlobeNewsWire